Skip to main content

Advertisement

Table 1 Summary of MOS-HIV effect sizes overall and in treatment naïve and treatment-experienced HIV-infected patients

From: Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies

Study Treatment Physical health summary Mental health summary
Mean change % change Effect size Mean change % change Effect size
Bucciardini et al. 2007 [13] ddI/d4T/EFV 4.7 9.4% −0.43 4.0 8.2% −0.40
ddI/d4T/NFV 0.7 1.5% −0.05 2.8 5.8% −0.28
ddI/d4T/EFV/NFV 2.0 4.2% −0.17 0.0 0.0% 0.00
Stangl et al. 2007a [23] HAART + weekly home visits 15.0* 38.3% −1.53 14.2* 35.5% −1.27
Average for treatment-naïve patients [weighted] 2.5 0.1 −0.55 2.3 0.1 −0.49
Nuesch et al. 2009b [17] Continuous treatment −1.3 −2.4% 0.20 0.8 1.5% 0.03
Scheduled treatment interruptionsc −1.2 −2.2% 0.19 0.4 0.8% −0.15
Huang et al. 2008 [14] TPV/r (tipranavir / ritonavir) 0.2 0.4% −0.02 1.4 2.9% −0.13
CPI/r (boosted comparitor PI) −0.3 −0.6% 0.03 1.7 3.6% −0.17
Powers et al. 2006 [18] Intermittent groupd 0.6 1.1% −0.07 3.2* 5.9% −0.37
Continuous groupe 1.0 1.9% −0.09 3.2 5.9% 0.00
Average for treatment-experienced patients [weighted] −0.2 0.0 0.04 1.5 0.0 −0.13
Overall mean [weighted] 0.7 0.1 −0.19 1.8 0.1 −0.27
  1. Mean change calculated as final score – baseline score. % change calculated as [(final score - baseline score) / baseline score] × 100. Effect size calculated as (final score – baseline score) / standard deviation of baseline score.
  2. *P<0.05; Note: significance of mean change scores not available for all studies; aProspective non-randomized controlled trial; bPatient population includes treatment-naïve and treatment-experienced patients (analyzed together); cCD4-guided treatment with threshold of 350 cells/μL for interruption/re-initiation of ARV therapy; d7 cycles of 4 weeks off/8 weeks on HAART; eContinue HAART regimen for 22 weeks.